ストックスクリーナーアプリを入手
27.44
0.83%
-0.23
アフターアワーズ：
27.38
-0.06
-0.22%
Cue Biopharma Inc (CUE) 最新ニュース
Law firm investigates Cue Biopharma's directors for possible breach of fiduciary duties. - Pluang
Shao-Lee Lin Discloses Investment at Cue Biopharma with 6.2% Stake - TradingView
Cue Biopharma (CUE) CEO builds stake with stock awards and cheap warrants - Stock Titan
Cue Biopharma, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Driehaus Capital Management Acquires New Stake in Cue Biopharma Inc (CUE) - GuruFocus
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock - Investing.com
Cue Biopharma VP Michael Meluzio disposes of $169,323 in stock By Investing.com - Investing.com South Africa
Cue Biopharma legal chief sells $265,627 in common stock - Investing.com
Cue Biopharma legal chief sells $265,627 in common stock By Investing.com - Investing.com Canada
Cue Biopharma (NASDAQ:CUE) VP Michael Vincent Meluzio Sells 5,628 Shares of Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) Insider Sells $265,664.61 in Stock - MarketBeat
Cue Biopharma (NASDAQ: CUE) exec's tax sell-to-cover after equity grant - Stock Titan
Cue Biopharma (CUE) Q2 Results Highlight High Price-to-Sales Ami - GuruFocus
Cue Biopharma (CUE) Leaps 10.04% to $34.2, Testing Key Resistance at $35.91Seasonality Effect - Vinanet
CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally? - Stocktwits
Cue Biopharma (NASDAQ:CUE) Lowered to "Hold" Rating by Wall Street Zen - MarketBeat
Cue Biopharma CEO Lin sells shares worth $1.6 million By Investing.com - Investing.com Canada
Cue Biopharma CEO Lin sells shares worth $1.6 million - Investing.com
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells $1,084,000.00 in Stock - MarketBeat
Insider Selling: Cue Biopharma (NASDAQ:CUE) CEO Sells 18,258 Shares - MarketBeat
Insider plans 58,258-share stock sale (NASDAQ: CUE) under Rule 144 - Stock Titan
Cue Biopharma (NASDAQ:CUE) Posts Quarterly Earnings Results, Misses Estimates By $22.45 EPS - MarketBeat
Cue Biopharma, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Cue Biopharma Q2 loss widens to $153.1M on non-cash charges - scanx.trade
Is Cue Biopharma Inc (CUE) Facing Financial Strain After Q2 Loss - GuruFocus
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights - The Manila Times
Cue Biopharma Q2 revenue more than doubles, net loss widens on one-time charges - TradingView
Cue Biopharma Raises $50M for CUE-221 Food Allergy Program - Stock Titan
Cue Biopharma Stock (CUE) Opinions on Management Changes and Phase 2 Data Prospects - Quiver Quantitative
Driehaus Capital discloses 6.96% Cue Biopharma (CUE) holding in Schedule 13G - Stock Titan
Cue Biopharma Inc. (NASDAQ: CUE)Dividends - intelligentinvestor.com.au
Cue Biopharma, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Cue Biopharma (CUE) registers 1.51M shares for stockholder resale after $50M raise - Stock Titan
Cue Biopharma (CUE) Expected to Announce Earnings on Tuesday - marketbeat.com
Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%Should You Sell? - MarketBeat
Cue Biopharma (CUE) Holds Steady Near $27 as Biotech Sector Digests MomentumEMA Signal - dars.gov.et
CUE Stock On Track For Best Day In History — Why Is Retail Optimistic? - Stocktwits
Cue Biopharma, Inc. expected to post a loss of $1.69 a shareEarnings Preview - TradingView
Cue Biopharma Inc (CUE) Stock News Today - TradingKey
Cue Biopharma Inc (CUE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cue Biopharma Appoints Veteran James Ahlers as CFO - The Globe and Mail
Cue Biopharma Appoints James Ahlers as Chief Financial Officer – SEC 8-K Filing Details - Minichart
Cue appoints James Ahlers as Chief Financial Officer - TradingView
Cue Biopharma (CUE) hires James Ahlers as CFO with equity and severance package - Stock Titan
Cue Biopharma, Inc. Announces Appointment of James Ahlers as Principal Financial Officer, Effective July 30, 2026 - marketscreener.com
Cue Biopharma names James Ahlers as chief financial officer By Investing.com - Investing.com Nigeria
Cue Biopharma Names James Ahlers CFO - Moomoo
Cue Biopharma names James Ahlers as chief financial officer - Investing.com
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - Yahoo Finance
Cue Biopharma appoints James M. Ahlers as CFO to steer clinical-stage growth - scanx.trade
Cue Biopharma Inc (CUE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CUE|Cue Biopharma Inc|Price:32.120|Chg%:-0.970 - TradingKey
Cue Biopharma Inc (CUE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cue Biopharma Company Profile & Introduction - Moomoo
Enterprise value to EBITDA forward of Cue Biopharma, Inc. – NASDAQ:CUE - TradingView
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):